Sandoz Group AG

Equities

SDZ

CH1243598427

Pharmaceuticals

Market Closed - Swiss Exchange 11:30:02 2024-05-17 am EDT 5-day change 1st Jan Change
31.99 CHF -0.87% Intraday chart for Sandoz Group AG -1.72% +18.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents MT
AstraZeneca, Merck Sue to Protect Lynparza Cancer Drug Patents MT
AstraZeneca, Merck Sue Over Alleged Cancer Drug Patents Infringement MT
Swiss Market Index Closes Higher; Sandoz Gains MT
SANDOZ : Sandoz’s improvements are worth betting on Alphavalue
SANDOZ : Q1 miss not a worry; expect another boost for the share price Alphavalue
Sandoz: 5% sales growth in Q1 CF
Transcript : Sandoz Group AG, Q1 2024 Sales/ Trading Statement Call, May 07, 2024
Sandoz Group Logs Growth in Q1 Net Sales, Affirms FY24 Outlook MT
Sandoz Announces Sales Results for the First Quarter 2024 CI
Sandoz Group Ag Reiterates Earnings Guidance for the Full Year 2024 CI
Global markets live: Adidas, Mercedes, McDonalds, Eli Lilly, PayPal, MicroStrategy, Tesla... Our Logo
Sandoz Group AG Announces Appointment of Graeme Pitkethly as Non-Executive Director and Chair of Its Audit, Risk and Compliance Committee CI
Sandoz Group AG Announces Board and Committee Appointments CI
Sandoz Group AG Approves Dividend, Payable on May 7, 2024 CI
Sandoz Reaches Agreement With Amgen Resolving All Patent Litigation DJ
Sandoz Group Settles Patent Disputes with Amgen MT
Sandoz reaches agreement with Amgen over patent dispute RE
Cigna to offer Humira rivals with $0 copay at specialty pharmacy RE
Swiss Market Index Closes Higher; UBS Slumps MT
Sandoz Upgrades Sandoz to Buy from Neutral, Boosts PT MT
Sandoz: boosted by broker upgrade CF
SANDOZ : UBS raises its recommendation CF
Sandoz: approval of Pyzchiva in Europe CF
European Commission Grants Marketing Authorization for Sandoz Biologic Therapy Pyzchiva MT
Chart Sandoz Group AG
More charts
Sandoz Group AG is a Switzerland based company which is active in healthcare technology industry. The Company operates in two businesses, Generics and Biosimilars. Generics business develops, manufacture and market active ingredients and finished dosage forms of small molecule pharmaceuticals, finished dosage forms of anti-infectives and active pharmaceutical ingredients and intermediates. Biosimilars business develops, manufacture and market protein-based and other biological products which are similar to another already approved biological medicines. Company’s product portfolio comprising Generics and Biosimilars covers all therapeutic areas for patient treatment such as cardiovascular, central nervous system, oncology, anti-infectives, pain and respiratory. The Company serves customers worldwide.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
35.25 USD
Average target price
39.18 USD
Spread / Average Target
+11.17%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. SDZ Stock
  4. News Sandoz Group AG
  5. European Commission Grants Marketing Authorization for Sandoz Biologic Therapy Pyzchiva
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW